Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC)

被引：1
|
作者：
Chen, Zhendong
Bai, Yuxian
Zhang, Tao
Ying, Jieer
Lin, Xiaoyan
Yang, Liu
Wang, Jun
Zhang, Juan
Yu, Fan
Fei, Cong
Huang, Ruiqi
Li, Jin
机构：
[1] Anhui Med Hosp, Second Hosp, Hefei, Peoples R China
[2] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[4] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[5] Fujian Med Univ Union Hosp, Fuzhou, Peoples R China
[6] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
[7] BeiGene Beijing Co Ltd, Beijing, Peoples R China
[8] BeiGene Beijing Co Ltd, Shanghai, Peoples R China
[9] Shanghai East Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.281
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
281
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: Prevalence and outcome dataTranslating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: prevalence and outcome data.
    Gardeazabal, Itziar
    Hierro, Cinta
    Viaplana, Cristina
    Nuciforo, Paolo
    Vivancos, Ana
    Mercade, Teresa Macarulla
    Garralda, Elena
    Eugenia Semidey, Maria
    Grau Bejar, Juan Francisco
    Dienstmann, Rodrigo
    Landolfi, Stefania
    Alsina, Maria
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?
    Bai, Rilan
    Chen, Naifei
    Liang, Tingting
    Li, Lingyu
    Lv, Zheng
    Lv, Xiaomin
    Cui, Jiuwei
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [23] Safety and Efficacy of Sitravatinib plus Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
    Khan, N.
    Newman, J.
    Rahman, H.
    Lee, C-S.
    Kohn, N.
    Seetharamu, N.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S373 - S374
  • [24] Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1+, locally advanced/metastatic, squamous NSCLC
    Gao, Bo
    Zhao, Jun
    Huang, Dingzhi
    Sun, Meili
    Ma, Zhiyong
    Chu, Qian
    Liu, Yunpeng
    Wang, Zhehai
    Li, Xin
    Li, Hui
    Zhang, Juan
    Sun, Jingchao
    Peng, Yanyan
    Wu, Yi-Long
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 124 - 124
  • [25] Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1+, locally advanced/metastatic, nonsquamous NSCLC
    Gao, Bo
    Zhao, Jun
    Wu, Jingxun
    Wang, Lifeng
    Sun, Meili
    Ma, Zhiyong
    Liu, Yunpeng
    Wang, Zhehai
    Li, Xin
    Li, Hui
    Zhang, Juan
    Sun, Jingchao
    Peng, Yanyan
    Wu, Yi-Long
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 123 - 124
  • [26] Phase Ib trial of cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with advanced hepatocellular carcinoma (HCC), gastric or gastroesophageal junction cancer (GC/GEJC), or colorectal cancer (CRC).
    Spencer, Kristen Renee
    Ramsingh, Giridharan
    Mohamed, Nehal
    Pal, Sumanta K.
    Rimassa, Lorenza
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [27] Efficacy and tolerability of bevacizumab (BEV) plus capecitabine and cisplatin (XP) in Chinese patients (pts) with locally advanced or metastatic gastric/gastroesophageal junction cancer (AGC): Results from the AVATAR study.
    Shen, Lin
    Li, Jin
    Xu, Jian-Ming
    Pan, Hong-Ming
    Dai, Guanghai
    Qin, Shukui
    Wang, Liwei
    Wang, Jinwan
    Yang, Zhenzhou
    Shu Yongqian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [28] SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer
    Li, Jin
    Bai, Yuxian
    Chen, Zhendong
    Ying, Jieer
    Guo, Yabing
    Fang, Weijia
    Zhang, Feng
    Xiong, Jianping
    Zhang, Tao
    Meng, Zhiqiang
    Zhang, Jingdong
    Ren, Zhenggang
    Hao, Chunyi
    Chen, Yajin
    Lin, Xiaoyan
    Pan, Hongming
    Zhou, Fuxiang
    Li, Xin
    Yu, Fan
    Zhang, Juan
    Zhang, Zhang
    Qin, Shukui
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (11)
  • [29] Phase I study to evaluate the safety, tolerability and preliminary efficacy of rivoceranib plus paclitaxel in advanced gastric or gastroesophageal junction (GEJ) cancer
    Ryu, M. H.
    Pande, A.
    Kim, J. H.
    Kang, Y-K.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1114 - S1114
  • [30] Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D).
    Bang, Yung-Jue
    Golan, Talia
    Lin, Chia-Chi
    Kang, Yoon-Koo
    Wainberg, Zev A.
    Wasserstrom, Heather
    Jin, Jin
    Mi, Gu
    McNeely, Samuel
    Laing, Naomi
    Goff, Laura Williams
    Fu, Siqing
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345